1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Clinical data of the 13 patients
Patient Gender Age at Onset (years) Age at Epilepsy (years) Seizure Frequency Drug IQ 1 F 1.5 1.1 1/month OXC, VPA, PHB 86 2 M 1.9 0.5 Free for 1 year CBZ 70 3 F 2.5 No epilepsy Aspirin 102 4 F 2.8 1.5 Free for 8 months LEV 76 5 F 8.9 0.6 Free for 8 years None 82 6 M 10.3 No epilepsy None 69 7 M 2.7 0.2 2/day OXC 60 8 M 4.3 0.4 A few per year OXC 71 9 F 6.0 0.3 A few per year OXC 60 10 M 6.0 0.5 10–30/day LEV, VPA 35 11 M 6.3 0.8 Free for 2 years CBZ, LEV 55 12 F 8.1 0.3 Free for 3 years CBZ 87 13 F 9.5 0.7 A few per year CBZ 60
Note:—F indicates female; M, male; OXC, oxcarbamazepine; VPA, valproate; PHB, phenobarbital; LEV, levetiracetam; CBZ, carbamazepine.